Open an account

Abbott Laboratories

ABT · NYSE

$102.45−$1.61 (−1.55%)TodayMarket closed ·
Prev close $104.06

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.

Employees
115,000
Headquarters
ABBOTT PARK, Illinois
Listed
Mar 1, 1937
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
abbott.com

ABT key statistics

Market cap
180.06B
Price-earnings ratio
33.57
Dividend yield
2.37%
Average volume
8.95M
Volume
9.97M
Open price
$105.53
High today
$105.62
Low today
$100.75
52 Week high
$132.03
52 Week low
$81.97

Abbott Laboratories (ABT) at a glance

Abbott Laboratories (ABT) last traded at $102.45, with a market cap of 180.06B, a price-to-earnings ratio of 33.57 and a dividend yield of 2.37%.

Today the stock has traded between $100.75 and $105.62. The current price is 1.7% above the day's low and 3.0% below its high.

Volume so far is 9.97M shares, in line with the average of 8.95M shares a day.

Over the past year Abbott Laboratories has ranged from $81.97 to $132.03, and now sits 41% of the way up that range.

Abbott Laboratories met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $1.31 per share against an estimate of $1.29.

The average analyst price target is $123.39, 20.4% above the current price, from 20 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 20 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 28 analystsAvg $123.39
Low
$104.03
Now
$102.45
High
$142.80

ABT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 1.1% on average.

  1. Q3 FY24: reported $1.21 per share against an estimate of $1.21
  2. Q4 FY24: reported $1.34 per share against an estimate of $1.36
  3. Q1 FY25: reported $1.09 per share against an estimate of $1.08
  4. Q2 FY25: reported $1.26 per share against an estimate of $1.27
  5. Q3 FY25: reported $1.30 per share against an estimate of $1.31
  6. Q4 FY25: reported $1.50 per share against an estimate of $1.51
  7. Q1 FY26: reported $1.15 per share against an estimate of $1.16
  8. Q2 FY26: reported $1.31 per share against an estimate of $1.29

ABT news

  • Press releasePRNewswire

    Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

  • Press releasePRNewswire

    Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

  • Press releasePRNewswire

    Abbott hosts conference call for third-quarter earnings

  • Press releasePRNewswire

    Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio

  • Press releasePRNewswire

    Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health

  • 3 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    Abbott declares 411th consecutive quarterly dividend

  • Press releasePRNewswire

    Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

Similar companies

Companies in the same industry as Abbott Laboratories

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.